SEARCH

SEARCH BY CITATION

References

  • Aguilar, L.K., Rooney, C.M. & Heslop, H.E. (1999) Lymphoproliferative disorders involving Epstein–Barr virus after hemopoietic stem cell transplantation. Current Opinion in Oncology, 11, 96101.
  • Antorini, A., Cingolani, A., De Luca, A., Gaidano, G., Ammassari, A., Larocca, L.M. & Ortona, L. (1999) Epstein–Barr virus in monitoring the response to therapy of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. Annals of Neurology, 5, 259261.
  • Armes, J.E., Angus, P., Southey, M.C., Battaglia, S.E., Ross, B.C., Jones, R.M. & Venter, D.J. (1994) Lymphoproliferative disease of donor origin arising in patients after orthotopic liver transplantation. Cancer, 74, 24362441.
  • Armitage, J.M., Kormos, R.L., Stuart, R.S., Fricker, F.J., Griffith, B.P., Nalesnik, M., Hardesty, R.L. & Dummer, J.S. (1991) Posttransplant lymphoproliferative disease in thoracic organ transplant patients: 10 years of cyclosporine-based immunosuppression. Journal of Heart and Lung Transplantation, 10, 877887.
  • Baldanti, F., Grossi, P., Furione, M., Simoncini, L., Sarasini, A., Comoli, P., Maccario, R., Fiocchi, R. & Gerna, G. (2000) High levels of Epstein–Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. Journal of Clinical Microbiology, 38, 613619.
  • Balfour, I.C., Wall, D., Luisiri, A., Sotelo, C. & Gross, T.G. (1999) Cyclophosphamide/Prednisone for combination immunosuppression and therapy of lymphoproliferative disease. Journal of Heart and Lung Transplantation, 18, 492495.
  • Barker, J.N., Martin, P.L., Coad, J.E., De For, T., Trigg, M.E., Kurtzberg, J., Weisdorf, D.J. & Wagner, J. (2001) Low incidence of Epstein–Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients. Biology of Blood and Marrow Transplantation, 7, 395399.
  • Beck, R., Westdorp, I., Jahn, G., Schafer, H., Kanz, L. & Einsele, H. (1999) Detection of Epstein–Barr virus DNA in plasma from patients with lymphoproliferative disease after allogeneic bone marrow or peripheral blood stem cell transplantation. Journal of Clinical Microbiology, 37, 34303431.
  • Ben-Ari, Z., Amlot, P., Lachmanan, S.R., Tur-Kaspa, R., Rolles, K. & Burroughs, A.K. (1999) Posttransplantation lymphoproliferative disorder in liver recipients: characteristics, management and outcome. Liver Transplantation and Surgery, 5, 184191.
  • Benkerrou, M., Jais, J.P., Leblond, V., Durandy, A., Sutton, L., Bordigoni, P., Garnier, J.L., Le Bidois, J., Le Deist, F., Blanche, S. & Fischer, A. (1998) Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood, 92, 31373147.
  • Bonini, C., Ferrari, G., Verzeletti, S., Servida, P., Zappone, E., Ruggieri, L., Ponzoni, M., Rossini, S., Mavilio, F., Traversari, C. & Bordignon, C. (1997) HSV-tk gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science, 276, 17191724.
  • Bordignon, C., Bonini, C., Verzeletti, S., Nobili, N., Maggioni, D., Traversari, C., Giavazzi, R., Servida, P., Zappone, E. & Benazzi, E. (1995) Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. Human Gene Therapy, 6, 813819.
  • Buda, A., Caforio, A., Calabrese, F., Fagiuoli, S., Pevere, S., Livi, U., Naccarato, R. & Burra, P. (2000) Lymphoproliferative disorders in heart transplant recipients: role of hepatitis C virus and Epstein–Barr virus infection. Transplant International, 13, S402S405.
  • Cavazzana, M., Bensoussan, D., Jabado, N., Haddad, E., Yvon, E., Moskwa, M., Tachet des Combes, A., Buisson, M., Morand, P., Virion, J.M., Le Deist, F. & Fischer, A. (1998) Prevention of EBV-induced B-lymphoproliferative disorder by ex vivo marrow B-cell depletion in HLA-phenoidentical or non-identical T-depleted bone marrow transplantation. British Journal of Haematology, 103, 543551.
  • Cheung, A.N.Y., Chan, A.C.L., Chung, L.P., Chan, T.M., Cheng, I.K.P. & Chan, K.W. (1998) Post-transplantion lymphoproliferative disorder of donor origin in a sex-mismatched renal allograft as proven by chromosome in situ hybridisation. Modern Pathology, 11, 99102.
  • Cohen, J.I. (1991) Epstein–Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine, 70, 137160.
  • Cohen, J.I. (2000) Epstein–Barr Virus infection. New England Journal of Medicine, 343, 481492.
  • Comoli, P., Labirio, M., Basso, S., Baldanti, F., Grossi, P., Furione, M., Vigano, M., Fiocchi, R., Rossi, G., Ginevri, F., Gridelli, B., Moretta, A., Montagna, D., Locatelli, F., Gerna, G. & Maccario, R. (2002) Infusion of autologous Epstein–Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood, 99, 25922598.
  • Cook, R.C., Connors, J.M., Gascoyne, R.D., Fradet, G. & Levy, R.D. (1999) Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. Lancet, 354, 16981699.
  • Curtis, R.E., Travis, L.B., Rowlings, P.A., Socie, G., Kingma, D.W., Banks, P.M., Jaffe, E.S., Sale, G.E., Horowitz, M.M., Witherspoon, R.P., Shriner, D.A., Weisdorf, D.J., Kolb, H.J., Sullivan, K.M., Sobocinski, K.A., Gale, R.P., Hoover, R.N., Fraumeni, J.F. & Deeg, H.J. (1999) Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood, 94, 22082216.
  • Davis, C.L. (1998) The antiviral prophylaxis of post-transplant lymphoproliferative disorder. Springer Seminars in Immunopathology, 20, 437453.
  • Davis, C.L., Wood, B.L., Sabath, D.E., Joseph, J.S., Stehman-Breen, C. & Broudy, V.C. (1998) Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation, 66, 17701779.
  • Dotti, G., Fiocchi, R., Motta, T., Gamba, A., Gotti, E., Gridelli, B., Borleri, G., Manzoni, C., Viero, P., Remuzzi, G., Barbui, T. & Rambaldi, A. (2000) Epstein–Barr virus negative lymphoproliferative disorders in long-term survivors after heart, kidney and liver transplant. Transplantation, 69, 827833.
  • Dotti, G., Fiocchi, R., Motta, T., Mammana, C., Gotti, E., Riva, S., Gridelli, B., Viero, P., Oldani, E., Cornelli, P., Remuzzi, G., Barbui, T. & Rambaldi, A. (2001) High toxicity and low response rate after chemotherapy in patients with advanced stage posttransplant lymphoproliferative disorders. Blood, 98, S343a. Abstract.
  • Durandy, A. (2001) Anti-B cell and anti-cytokine therapy for the treatment of post-transplant lymphoproliferative disorder: past, present and future. Transplant Infectious Disease, 3, 104107.
  • Emanuel, D.J., Lucas, K.G., Mallory, G.B., Edwards-Brown, M.K., Pollok, K.E., Conrad, P.D., Robertson, K.A. & Smith, F.O. (1997) Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes. Transplantation, 63, 16911694.
  • Ernberg, I. & Andersson, J. (1986) Acyclovir efficiently inhibits oropharyngeal excretion of Epstein–Barr virus in patients with acute infectious mononucleosis. Journal of General Virology, 67, 22672272.
  • Van Esser, J.W.J., Van Der Holt, B., Meijer, E., Niesters, H.G.M., Trenschel, R.T., Thijsen, S.F.T., Van Loon, A.M., Frassoni, F., Bacigalupo, A., Schaefer, U.W., Osterhaus, A.D.M.E., Gratama, J.W., Lowenberg, B., Verdonck, L.F. & Cornelissen, J.J. (2001a) Epstein–Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood, 98, 972978.
  • Van Esser, J.W.J., Niesters, H.G.M., Thijsen, S.F.T., Meijer, E., Osterhaus, A.D.M.E., Wolthers, K.C., Boucher, C.A.B., Gratama, J.W., Budel, L.M., Van Der Holt, B., Van Loon, A.M., Lowenberg, B., Verdonck, L.F. & Cornelissen, J.J. (2001b) Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein–Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. British Journal of Haematology, 113, 814821.
  • Van Esser, J.W.J., Niesters, H.G.M., Van Der Holt, B., Meijer, E., Osterhaus, A.D.M.E., Gratama, J.W., Verdonck, L.F., Lowenberg, B. & Cornelissen, J.J. (2002) Prevention of Epstein–Barr virus-lymphoproliferative disease by molecular monitoring and pre-emptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood, 99, 4364–4369.
  • Faro, A. (1998) Interferon-alpha and its effects on post-transplant lymphoproliferative disorders. Springer Seminars in Immunopathology, 20, 425436.
  • Faye, A., Quartier, P., Reguerre, Y., Lutz, P., Carret, A.S., Dehee, A., Rohrlich, P., Peuchmaur, M., Matthieu-Boue, A., Fischer, A. & Vilmer, E. (2001) Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. British Journal of Haematology, 115, 112118.
  • Finn, L., Reyes, J., Bueno, J. & Yunis, E. (1998) Epstein–Barr virus infection in children after transplantation of the small intestine. American Journal of Surgical Pathology, 22, 299309.
  • Fischer, A., Blanche, S., Le Bidois, J., Bordigoni, P., Garnier, J.L., Niaudet, P., Morinet, F., Le Deist, F., Fischer, A.M., Griscelli, C. & Hirn, M. (1991) Anti B-cell monoclonal antibodies in the treatment of severe posttransplant B–cell lymphoproliferative syndrome following bone marrow and organ transplantation. New England Journal of Medicine, 324, 14511456.
  • Fohrer, C., Koumarianou, A., Caillard, S., Campos, F., Lioure, B., Maloisel, F., Woeghl-Jaegle, M.L., Ellero, B., Epailly, E., Natarajan-Ame, S., Moulin, B., Chenard, M.P. & Herbrecht, R. (2001) Safety and efficacy of low-dose ACVBP chemotherapy for post-transplant lymphoproliferative disorders (PTLD). a report of 27 cases from a single institution. Blood, 98, S341a. Abstract.
  • Fontan, J., Bassignot, A., Mougin, C., Cahn, J.Y. & Laboratory, M. (1998) Detection of Epstein–Barr virus DNA in serum of transplanted patients: a new diagnostic guide for lymphoproliferative diseases. Leukemia, 12, 772775.
  • Garrett, T.J., Chadburn, A., Barr, M.L., Drusin, R.E., Chen, J.M., Schulman, L.L., Smith, C.R., Reison, D.S., Rose, E.A., Michler, R.E. & Knowles, D.M. (1993) Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy. Cancer, 72, 27822785.
  • Gartner, B.C., Schafer, H., Marggraff, K., Eisele, G., Schafer, M., Roemer, K., Laws, H.J., Sester, U., Einsele, H. & Mueller-Lantzsch, N. (2002) Evaluation of use of Epstein–Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease. Journal of Clinical Microbiology, 40, 351358.
  • George, D., Barnett, L., Boulad, F., Childs, B., Castro-Malaspina, H., Jakubowski, A., Kernan, N.A., Papadopoulos, E., Small, T.N., Szabolcs, P., Young, J., Koulova, L. & O'Reilly, R.J. (1998) Semi-quantitative PCR analysis of genomic EBV DNA post-BMT allows close surveillance of patients at risk for development of EBV lymphoproliferative disorders allowing prompt intervention. Blood, 92, S 437a. Abstract.
  • Gerritsen, E.J., Hermans, J., Van Den Berg, H., Haraldsson, A., Van Tol, M.J., Van Den Bergh, R.L., Waaijer, J.L., Kroes, A.C., Kluin, P.M. & Vossen, J.M. (1996) Risk factors for developing EBV-related B cell lymphoproliferative disorders after non-HLA-identical BMT in children. Bone Marrow Transplantation, 18, 377382.
  • Gonzalez-Barca, E., Domingo-Domenech, E., Cabrera, J., Altes, A., Capote, F., De Sanjose, S., Petit, J., Granena, A. & De Sevilla, A.F. (2001) Spanish multicenter study of post-transplant lymphomas: pathology, clinical presentation and outcome. Blood, 98, S338a. Abstract.
  • Van Gorp, J., Doornewaard, H., Verdonck, L.F., Klopping, C., Vos, P.F. & Van Den Tweel, J.G. (1994) Posttransplant T cell lymphoma. Cancer, 73, 30643072.
  • Gottschalk, S., Ng, C.Y.C., Perez, M., Smith, C.A., Sample, C., Brenner, M.K., Heslop, H.E. & Rooney, C.M. (2001) An Epstein–Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood, 97, 835843.
  • Gratama, J.W., Oosterveer, M.A.P., Zwaan, F.E., Lepoutre, J., Klein, G. & Ernberg, I. (1988) Eradication of Epstein–Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. Proceedings of the National Academy of Science of the United States of America, 85, 86938696.
  • Gratama, J.W., Lenette, E.T., Lonnqvist, M.A.P., Klein, G., Ringden, O. & Ernberg, I. (1992) Detection of multiple Epstein–Barr viral strains in allogeneic bone marrow transplantation. Journal of Medical Virology, 37, 3947.
  • Green, M., Kaufmann. M., Wilson, J. & Reyes, J. (1997) Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein–Barr virus disease after liver transplantation in children. Clinical Infectious Diseases, 25, 13441349.
  • Gross, T.G., Hinrichs, S.H., Davis, J.R., Mitchell, D., Bishop, M.R. & Wagner, J.E. (1998) Depletion of EBV-infected cells in donor marrow by counterflow elutriation. Experimental Hematology, 26, 395399.
  • Gross, T.G., Steinbuch, M., DeFor, T., Shapiro, R.S., McGlave, P., Ramsay, N.K.C., Wagner, J.E. & Filipovich, A.H. (1999) B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplantation, 23, 251258.
  • Gruhn, B., Meerbach, A., Egerer, R., Mentzel, H.J., Hafer, R., Ringelmann, F., Sauerm, M., Hermann, J. & Zintl, F. (1999) Successful treatment of Epstein–Barr virus-induced transverse myelitis with ganciclovir and cytomegalovirus hyperimmune globulin following unrelated bone marrow transplantation. Bone Marrow Transplantation, 24, 13551358.
  • Gruhn, B., Meerbach, A., Hafer, R., Zell, R., Berndt, A., Kosmehl, H., Wutzler, P. & Zintl, F. (2001) Early diagnosis and pre-emptive therapy of Epstein–Barr virus-associated lymphoproliferative disease following hematopoietic stem cell transplantation. Blood, 98, S393a. Abstract.
  • Gustafsson, A., Levitsky, V., Frisan, T., Dalianis, T., Ljungman, P., Ringden, O., Winiarski, J., Emberg, I. & Masucci, M.G. (2000) Epstein–Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T-cells. Blood, 95, 807814.
  • Hale, G. & Waldmann, H. (1998) Risks of developing Epstein–Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. Blood, 91, 30793083.
  • Hanel, M., Fiedler, F. & Thorns, C. (2001) Anti-CD20 monoclonal antibody (rituximab) and cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement. Onkologie, 24, 491494.
  • Haque, T. & Crawford, D.H. (1999) The role of adoptive immunotherapy in the prevention and treatment of lymphoproliferative disease following transplantation. British Journal of Haematology, 106, 309316.
  • Haque, T., Thomas, J.A., Falk, K.I., Parratt, R., Hunt, B.J., Yacoub, M. & Crawford, D.H. (1996) Transmission of donor Epstein–Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients. Journal of General Virology, 77, 11691172.
  • Haque, T., Amlot, P.L., Helling, N., Thomas, J.A., Sweny, P., Rolles, K., Burroughs, A.K., Prentice, H.G. & Crawford, D.H. (1998) Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients. Journal of Immunology, 160, 62046209.
  • Haque, T., Taylor, C., Wilkie, G.M., Murad, P., Amlot, P.L., Beath, S., McKiernan, P.J. & Crawford, D.H. (2001) Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein–Barr virus-specific cytotoxic T cells. Transplantation, 72, 13991402.
  • Hoshino, Y., Kimura, H., Tanaka, N., Tsuge, I., Kudo, K., Horibe, K., Kato, K., Matsuyama, T., Kikuta, A., Kojima, S. & Morishima, T. (2001) Prospective monitoring of the Epstein–Barr virus DNA by a real-time quantitative polymerase chain reaction after allogeneic stem cell transplantation. British Journal of Haematology, 115, 105111.
  • Kanegane, H., Wakiguchi, H., Kanegane, C., Kurashige, T., Miyawaki, T. & Tosato, G. (1999) Increased cell-free viral DNA in fatal cases of chronic active Epstein–Barr virus infection. Clinical Infectious Diseases, 28, 906909.
  • Keever-Taylor, C.A., Konings, S., Orentas, R.J., Bellissimo, D.B., Davies, B., Behn, B., Margolis, D.A. & Burns, W. (2001) H. Two week exposure of B lymphoblastoid cell lines (BLCL) to 100μM acyclovir does nor prevent release of infectious Epstein–Barr virus after 75 GY irradiation. Blood, 98, S358b. Abstract.
  • Kentos, A., Knoop, C., Wissing, M., Robin, V., Remmelinx, M., Garbar, C., Goldman, S., Housni, H.E., Feremans, W. & Estenne, M. (2001) Anti-CD20 monoclonal antibody as first-line treatment of post-transplant B-lymphoproliferative disorders in solid organ transplant recipients. A report of 8 cases observed in a single center. Blood, 98, S344a. Abstract.
  • Khanna, R., Bell, S., Sherritt, M., Galbraith, A., Burrows, S.R., Rafter, L., Clarke, B., Slaughter, R., Falk, M.C., Douglass, J., Wiliams, T., Elliott, S.L. & Moss, D.J. (1999) Activation and adoptive transfer of Epstein–Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proceedings of the National Academy of Science of the United States of America, 96, 1039110396.
  • Kieff, E. & Rickinson, A.B. (2001) Epstein–Barr virus and its replication. In: Fields Virology (ed. by D.M.Knipe & P.M.Howley), pp. 25112627. Lippincott Williams & Wilkins, Philadelphia.
  • Kimura, H., Morita, M., Yabuta, Y., Kuzushima, K., Kato, K., Kojima, S., Matsuyama, T. & Morishima, T. (1999) Quantitative analysis of Epstein–Barr virus load by using a real-time PCR assay. Journal of Clinical Microbiology, 37, 132136.
  • Kuehnle, I., Huls, M.H., Liu, Z., Semmelmann, M., Krance, R.A., Brenner, M.K., Rooney, C.M. & Heslop, H.E. (2000) CD20 monoclonal antibody (rituximab) for therapy of Epstein–Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood, 95, 15021505.
  • Larson, R.S., Scott, M.A., McCurley, T.L. & Vnencak-Jones, C.L. (1996) Microsatellite analysis of posttransplant lymphoproliferative disorders: determination of donor/recipient origin and identification of putative lymphomagenic mechanism. Cancer Research, 56, 43784381.
  • Lazarovits, A.I., Tibbles, L.A., Grant, D.R., Ghent, C.N., Wall, W.J., White, M.J. & Joncas, J.H. (1994) Anti-B cell antibodies for the treatment of monoclonal Epstein–Barr virus-induced lymphoproliferative syndrome after multivisceral transplantation. Clinical and Investigative Medicine, 17, 621625.
  • Le Meur, Y., Potelune, N., Jaccard, A., Petit, B., Bordessoule, D., Peyronnet, P., Ranger, S., Labrousse, F. & Leroux, R.C. (1998) Lymphoproliferative syndromes after renal transplantation. Nephrologie, 19, 255261.
  • Leblond, V., Sutton, L., Dorent, R., Davi, F., Bitker, M.O., Gabarre, J., Charlotte, F., Ghoussoub, J.J., Fourcade, C. & Fischer, A. (1995) Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single centre. Journal of Clinical Oncology, 13, 961968.
  • Leblond, V., Davi, F., Charlotte, F., Dorent, R., Bitker, M.O., Sutton, L., Gandjbakhch, I., Binet, J.L. & Raphael, M. (1998) Posttransplant lymphoproliferative disorders not associated with Epstein–Barr virus: a distinct entity? Journal of Clinical Oncology, 16, 20522059.
  • Leblond, V., Dhedin, N., Bruneel, M.F.M., Choquet, S., Hermine, O., Porcher, R., Quoc, S.N., Davi, F., Charlotte, F., Dorent, R., Barrou, B., Vernant, J.P., Raphael, M. & Levy, V. (2001) Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. Journal of Clinical Oncology, 19, 772778.
  • Limaye, A.P., Huang, M.L., Atienza, E.E., Ferrenberg, J.M. & Corey, L. (1999) Detection of Epstein–Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders. Journal of Clinical Microbiology, 37, 11131116.
  • Lin, J.C., Chen, K.Y., Wang, W.Y., Jan, J.S., Tsai, C.S. & Wei, Y.H. (2001) Detection of Epstein–Barr virus DNA in peripheral-blood cells of patients with nasopharyngeal carcinoma: relationship to distant metastasis and survival. Journal of Clinical Oncology, 19, 26072615.
  • Liu, Z., Wilson, J.M., Jones, M.C., Khan, S.P., Krance, R.A., Brenner, M.K., Rooney, C.M., Heslop, H.E. & Gee, A.P. (1999) Addition of B cell depletion of donor marrow with anti-CD20 antibody to a T cell depletion regimen for prevention of EBV lymphoma after bone marrow transplantation. Blood, 94, S638a. Abstract.
  • Ljungman, P. (2001) Prophylaxis against herpesvirus infections in transplant recipients. Drugs, 61, 187196.
  • Lo, Y.M.D., Chan, L.Y.S., Chan, A.T.C., Leung, S.F., Lo, K.W., Zhang, J., Lee, J.C.K., Hjelm, N.M., Johnson, P.J. & Huang, D.P. (1999) Quantitative and temporal correlation between circulating cell-free Epstein–Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Research, 59, 54525455.
  • Lo, Y.M.D., Chan, A.T.C., Chan, L.Y.S., Leung, S.F., Lam, C.W., Huang, D.P. & Johnson, P.J. (2000) Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein–Barr virus DNA. Cancer Research, 60, 68786881.
  • De Luca, A., Antorini, A., Cingolani, A., Larocca, L.M., Linzalone, A., Ammassari, A., Scerrati, M., Roselli, R., Tamburrini, E. & Ortona, L. (1995) Evaluation of cerebrospinal fluid EBV-DNA and IL-10 markers for in vivo diagnosis of AIDS-related primary central nervous system lymphoma. British Journal of Haematology, 90, 844849.
  • Lucas, K.G., Burton, R.L., Zimmerman, S.E., Wang, J., Cornetta, K.G., Robertson, K.A., Lee, C.H. & Emanuel, D.J. (1998a) Semiquantitative Epstein–Barr virus polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood, 91, 36543661.
  • Lucas, K.G., Filo, R., Heilman, D.K., Lee, C.H. & Emanuel, D.J. (1998b) Semiquantitative Epstein–Barr virus polymerase chain reaction analysis of peripheral blood from organ transplant patients at risk for the development of lymphoproliferative disease. Blood, 92, 39763980. (Letter).
  • Luxton, J.C., Williams, I. & Crawford, D.H. (1993) Epstein–Barr virus infection of HIV-seropositive individuals is transiently suppressed by high-dose acyclovir treatment. AIDS, 7, 13371343.
  • Manez, R., Breinig, M.C., Linden, P., Wilson, J., Torre-Cisneros, J., Kusne, S., Dummer, S. & Ho, M. (1997) Post-transplant lymphoproliferative disease in primary Epstein–Barr virus infection after liver transplantation: the role of cytomegalovirus disease. Journal of Infectious Diseases, 176, 14621467.
  • Marshall, N.A., Howe, J.G., Formica, R., Krause, D., Wagner, J.E., Berliner, N., Crouch, J., Pilip, I., Cooper, D., Blazar, B.R., Seropian, S. & Pamer, E.G. (2000) Rapid reconstitution of Epstein–Barr virus-specific T lymphocytes following allogeneic stem cell transplantation. Blood, 96, 28142821.
  • McDiarmid, S.V., Jordan, S., Lee, G.S., Toyoda, M., Goss, J.A., Vargas, J.H., Martin, M.G., Bahar, R., Maxfield, A.L., Ament, M.E. & Busuttil, R.W. (1998) Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation, 66, 16041611.
  • McGuirk, J.P., Seropian, S., Smith, B., Stoddart, L. & Cooper, D.L. (1999) Use of rituximab and irradiated donor-derived lymphocytes to control Epstein–Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation. Bone Marrow Transplantation, 24, 12531258.
  • Meerbach, A., Gruhn, B., Egerer, R., Reischl, U., Zintl, F. & Wutzler, P. (2001) Semiquantitative PCR analysis of Epstein–Barr virus DNA in clinical samples of patients with EBV-associated diseases. Journal of Medical Virology, 65, 348357.
  • Meijer, E., Slaper-Cortenbach, I.C.M., Thijsen, S.F.T., Dekker, A.W. & Verdonck, L.F. (2002) Increased incidence of EBV-associated lymphoproliferative disorders after allogeneic stem cell transplantion from matched unrelated donors due to a change of T-cell depletion technique. Bone Marrow Transplantation, 29, 335339.
  • Micallef, I.N., Chanabhai, M., Gascoyne, R.D., Shepherd, J.D., Fung, H.C., Nantel, S.H., Toze, C.L., Klingemann, H.G., Sutherland, H.J., Hogge, D.E., Nevill, T.J., Le, A. & Barnett, M.J. (1998) Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience. Bone Marrow Transplantation, 22, 981987.
  • Milpied, N., Vasseur, B., Parquet, N., Garnier, J.L., Antoine, C., Quartier, P., Carret, A.S., Bouscary, D., Faye, A., Bourbigot, B., Reguerre, Y., Stoppa, A.M., Bourguard, P., Hurault de Ligny, B., Dubief, F., Mathieu-Boue, A. & Leblond, V. (2000) Humanized anti CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder. a retrospective analysis on 32 patients. Annals of Oncology, 11, S113S116.
  • Montone, K.T., Hodinka, R.L., Salhany, K.E., Lavi, E., Rostami, A. & Tomaszewski, J.E. (1996) Identification of Epstein–Barr virus lytic activity in posttransplantation lymphoproliferative disease. Modern Pathology, 9, 621630.
  • Nalesnik, M.A. (1998) Clinical and pathological features of post-transplant lymphoproliferative disorders. Springer Seminars in Immunopathology, 20, 325342.
  • Nalesnik, M.A., Rao, A.S., Furukawa, H., Pham, S., Zeevi, A., Fung, J.J., Klein, G., Gritsch, H.A., Elder, E., Whiteside, T.L. & Starzl, T.E. (1997) Autologous lymphokine-activated killer cell therapy of Epstein–Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation, 63, 12001205.
  • Nelson, B.P., Nalesnik, M.A., Bahler, D.W., Locker, J., Fung, J.J. & Swerdlow, S.H. (2000) Epstein–Barr virus negative post-transplant lymphoproliferative disorders. American Journal of Surgical Pathology, 24, 375385.
  • O'Reilly, R.J., Small, T.N., Papadopoulos, E., Lucas, K., Lacerda, J. & Koulova, L. (1997) Biology and adoptive cell therapy of Epstein–Barr virus associated lymphoproliferative disorders in recipients of marrow allografts. Immunological Reviews, 157, 195216.
  • Ohga, S., Kubo, E., Nomura, A., Takada, H., Suga, N., Ishii, E., Suminoe, A., Inamitsu, T., Matsusaki, A., Kasuga, N. & Hara, T. (2001) Quantitative monitoring of circulating Epstein–Barr virus DNA for predicting the development of posttransplantation lymphoproliferative disease. International Journal of Hematology, 73, 323326.
  • Penn, I. (1998) The role of immunosuppression in lymphoma formation. Springer Seminars in Immunopathology, 20, 343355.
  • Portolani, M., Cermelli, C., Meacci, M., Pietrosemoli, P., Sabbatini, A.M., Cerri, M.C., Guaraldi, G. & De Rienzo, B. (1999) Epstein–Barr virus DNA in the cerebrospinal fluid of patients with human immunodeficiency virus infection and central nervous system disorders. New Microbiologica, 22, 369374.
  • Preitsakis, J.K. & Keay, S. (2001) Diagnosis and management of posttransplant lymphoproliferative disorder in solid organ transplant recipients. Clinical Infectious Diseases, 33, S38S46.
  • Raymond, E., Tricottet, V., Samuel, D., Reynes, M., Bismuth, H. & Misset, J.L. (1995) Epstein–Barr virus-related localized hepatic lymphoproliferative disorders after liver transplantation. Cancer, 76, 13441351.
  • Rea, D., Delecluse, H.J., Hamilton-Dutoit, S.J., Marelle, L., Joab, I., Edelman, L., Finet, J.F. & Raphael, M. (1994) Epstein–Barr virus latent and replicative gene expression in post-transplant lymphoproliferative disorders and AIDS-related non-Hodgkin's Lymphomas. Annals of Oncology, 5, S113S116.
  • Riddler, S.A., Breinig, M.C. & McKnight, J.L.C. (1994) Increased levels of circulating Epstein–Barr virus (EBV) -infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid organ transplant recipients. Blood, 84, 972984.
  • Rogers, B.B., Sommerauer, J., Quan, A., Timmons, C.F., Dawson, D.B., Scheuermann, R.H., Krisher, K. & Atkins, C. (1998) Epstein–Barr virus polymerase chain reaction and serology in pediatric post-transplant lymphoproliferative disorder: three year experience. Pediatric and Developmental Pathology, 1, 480486.
  • Rooney, C.M., Loftin, S.K., Holladay, M.S., Brenner, M.K., Krance, R.A. & Heslop, H.E. (1995a) Early identification of Epstein–Barr virus-associated post-transplantation lymphoproliferative disease. British Journal of Haematology, 89, 98103.
  • Rooney, C.M., Smith, C.A., Ng, C.Y.C., Loftin, S.K., Li, C., Krance, R.A., Brenner, M.K. & Heslop, H.E. (1995b) Use of gene-modified virus-specific T lymphocytes to control Epstein–Barr-virus-related lymphoproliferation. Lancet, 345, 913.
  • Rooney, C.M., Smith, C.A., Ng, C.Y.C., Loftin, S.K., Sixbey, J.W., Gan, Y., Srivastava, D.K., Bowman, L.C., Krance, R.A., Brenner, M.K. & Heslop, H.E. (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein–Barr virus-induced lymphoma in allogeneic transplant recipients. Blood, 92, 15491555.
  • Rowe, M., Niedobitek, G. & Young, L.S. (1998) Epstein–Barr virus gene expression in post-transplant lymphoproliferative disorders. Springer Seminars in Immunopathology, 20, 389403.
  • Savoldo, B., Goss, J., Liu, Z., Huls, M.H., Doster, S., Gee, A.P., Brenner, M.K., Heslop, H.E. & Rooney, C.M. (2001) Generation of autologous Epstein–Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation, 72, 10781086.
  • Schafer, H., Berger, C., Aepinus, C., Hebart, H., Beck, R., Kaiserling, E., Kanz, L., Einsele, H. & Knecht, H. (2001) Molecular pathogenesis of Epstein–Barr virus associated posttransplant lymphomas: new insights through latent membrane protein 1 fingerprinting. Transplantation, 72, 492496.
  • Schneider, U., Ruhnke, M., Delecluse, H.J., Stein, H. & Huhn, D. (2000) Regression of Epstein–Barr virus-associated lymphoproliferative disorders in patients with acquired immunodeficiency syndrome during therapy with foscarnet. Annals of Hematology, 79, 214216.
  • Shapiro, R.S., McClain, K., Frizzera, G., Gajl-Peczalska, K.J., Kersey, J.H., Blazar, B.R., Arthur, D.C., Patton, D.F., Greenberg, J.S., Burke, B., Ramsay, N.K.C., McGlave, P. & Filipovich, A.H. (1988) Epstein–Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood, 71, 12341243.
  • Sirvent-von Bueltzingsloewen, A., Morand, P., Buisson, M., Souillet, G., Chambost, J.L. & Bordigoni, P. (2002) A prospective study of Epstein–Barr virus load in 85 hematopoietic stem cell transplants. Bone Marrow Transplantation, 29, 2128.
  • Sixbey, J.W. & Pagano, J.S. (1985) Epstein–Barr virus transformation of human B lymphocytes despite inhibition of viral polymerase. Journal of Virology, 53, 299301.
  • Smets, F., Vajro, P., Cornu, G., Reding, R., Otte, J.B. & Sokal, E. (2000) Indications and results of chemotherapy in children with posttransplant lymphoproliferative disease after liver transplantation. Transplantation, 69, 982984.
  • Stevens, S.J.C., Verschuuren, E.A.M., Pronk, I., Van Der Bij, W., Harmsen, M.C., Hauw the, T., Meijer, C.J.L.M., Van Den Brule, A.J.C. & Middeldorp, J.M. (2001) Frequent monitoring of Epstein–Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood, 97, 11651171.
  • Swinnen, L.J., Costanzo-Nordin, M.K., Fisher, S.G., O'Sullivan, E.J., Johnson, M.R., Heroux, A.L., Dizikes, G.J., Pifarre, R. & Fisher, R.I. (1990) Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. New England Journal of Medicine, 323, 17231728.
  • Swinnen, L.J., Mullen, G.M., Carr, T.J., Costanzo, M.R. & Fisher, R.I. (1995) Aggressive treatment for postcardiac transplant lymphoproliferation. Blood, 86, 33333340.
  • Tynell, E., Aurelius, E., Brandell, A., Julander, I., Wood, M., Yao, Q.Y., Rickinson, A., Akerlund, B. & Anderson, J. (1996) Acyclovir and prednisolone treatment of acute infectious mononucleosis: a multicenter double-blind, placebo-controlled study. Journal of Infectious Diseases, 174, 324331.
  • Wagner, H.J., Wessel, M., Jabs, W., Smets, F., Fischer, L., Offner, G. & Bucsky, P. (2001a) Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein–Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation, 72, 10121019.
  • Wagner, J.H., Cheng, Y.C., Liu, Z., Savoldo, B., Huls, M.H., Gee, A.P., Heslop, H.E. & Rooney, C.M. (2001b) Monitoring of transplanted patients at risk of Epstein–Barr virus (EBV)-induced lymphoproliferative disorder (LPD) by real time PCR quantification of EBV DNA in peripheral blood. Blood, 98, S480a. Abstract.
  • Walker, R.C., Marshall, W.F., Strickler, J.G., Wiesner, R.H., Velosa, J.A., Habermann, T.M., McGregor, C.G.A. & Paya, C.V. (1995) Pretransplantation assessment of the risk of lymphoproliferative disorder. Clinical Infectious Diseases, 20, 13461353.
  • Watts, R.G., Hilliard, L.M. & Berkow, R.L. (2001) Tailored chemotherapy for non-Hodgkin's lymphoma arising in the setting of post-transplant lymphoproliferative disease following solid organ transplantation. Blood, 98, S253b. Abstract.
  • Yamamoto, M., Kimura, H., Hironaka, T., Hirai, K., Hasegawa, S., Kuzushima, K., Shibata, M. & Morishima, T. (1995) Detection and quantification of virus DNA in plasma of patients with Epstein–Barr virus-associated diseases. Journal of Clinical Microbiology, 33, 17651768.
  • Yao, Q.Y., Ogan, P., Rowe, M., Wood, M. & Rickinson, A.B. (1989) Epstein–Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers. International Journal of Cancer, 43, 6771.
  • Zilz, N.D., Olson, L.J. & McGregor, C.G. (2001) Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation. Journal of Heart and Lung Transplantation, 20, 770772.
  • Zingg, W., Bossart, W., Berli, E. & Nadal, D. (1999) Detection and quantification of cell-free Epstein–Barr virus by polymerase chain reaction and subsequent DNA enzyme immunoassay. Journal of Virological Methods, 79, 141148.
  • Zompi, S., Tulliez, M., Conti, F., Leblond, V., Gaulard, P., Blanche, P., Durand, F., Ghandi, D., Dreyfus, F., Louvel, A., Calmus, Y. & Bouscary, D. (2000) Rituximab for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: a report of three cases. Journal of Hepatology, 32, 521527.
  • Zutter, M.M., Martin, P.J., Sale, G.E., Shulman, H.M., Fisher, L., Thomas, E.D. & Durnam, D.M. (1988) Epstein–Barr virus lymphoproliferation after bone marrow transplantation. Blood, 72, 520529.